Reporting Cost-effectiveness Analyses With Confidence

To the Editor. —One of the recommendations made by Dr Siegel and colleagues1 in their article on reporting cost-effectiveness analyses is that cost-effectiveness ratios should not appear for options that are less effective but more costly than an alternative (ie, are dominated).We agree with this approach when costs and effects are expressed as point estimates.2 However, the increasing frequency with which pharmacoeconomic evaluations are …